氟达拉滨、阿糖胞苷、伊达比星和粒细胞集落刺激因子（FLAG-IDA）方案治疗高危髓系恶性肿瘤患者

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.

作者信息

de la Rubia Javier, Regadera Ana, Martín Guillermo, Cervera José, Sanz Guillermo, Martínez Jesús, Jarque Isidro, García Inmaculada, Andreu Rafael, Moscardó Federico, Jiménez Carmen, Mollá Susana, Benlloch Luis, Sanz Miguel

机构信息

Hematology Service, University Hospital La Fe, Valencia, Spain.

出版信息

Leuk Res. 2002 Aug;26(8):725-30. doi: 10.1016/s0145-2126(02)00003-6.

DOI:10.1016/s0145-2126(02)00003-6

PMID:12191567

Abstract

Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity.

摘要

45例高危髓系恶性肿瘤患者（32例急性髓系白血病和13例高危骨髓增生异常综合征）接受了氟达拉滨、阿糖胞苷、伊达比星和粒细胞集落刺激因子（FLAG-IDA）治疗。24例（53%）患者达到完全缓解（CR），5例（11%）部分缓解。以肺部受累为主的感染是最常见的与治疗方案相关的毒性反应。黏膜炎（15例患者）和肺部毒性（19例患者）是最常观察到的非血液学副作用。有4例早期死亡，12例患者出现耐药疾病。12个月时的总生存率（OS）为40%。FLAG-IDA方案在高危髓系恶性肿瘤患者中显示出明显的抗白血病活性，且毒性可接受。